Massachusetts General Hospital – CFN Media

TRYP THERAPEUTICS RECEIVES CONFIRMATION FROM FDA TO PROCEED WITH PHASE 2A CLINICAL TRIAL IN PATIENTS WITH IBS AT MASSACHUSETTS GENERAL HOSPITAL

Kelowna Canada, (July 13 2023) — Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF)…

Ryan Allway
July 13, 2023

Top News

Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital

KELOWNA, BC / ACCESSWIRE / May 24, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) (“Tryp” or…

Ryan Allway
May 24, 2023

Top News

Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)

KELOWNA, BC / ACCESSWIRE / January 3, 2023 /Tryp Therapeutics, Inc. (CSE:TRYP)…

Ryan Allway
January 3, 2023

Don Kreski

Robin Lefferts

Ryan Allway

Ryan has been a financial writer for more than a decade, covering…

Cardiol’s Favorable Phase 2 Results Set the Table for Advanced Clinical Trials

Cardiol Therapeutics Inc. (Nasdaq: CRDL) (TSX: CRDL) recently presented excellent…

Robin Lefferts
November 20, 2024

Aduro Clean Technologies Engages Global Leader Zeton for Design and Fabrication of Hydrochemolytic™ Pilot Plant

Milestone Project to Demonstrate Aduro’s Modular, Scalable Solution for Converting…

Ryan Allway
November 19, 2024

IKE Tech LLC and Ispire Technology Inc. Announce Positive Pre-PMTA Submission Meeting with the FDA

Seeks Authorization for Pioneering Point-of-Use Identity and Age Verification…

Ryan Allway
November 18, 2024

Healthcare Stocks

Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation maintained…

Ryan Allway
November 18, 2024